On January 14, 2021, Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC Pink: INNPF), headquartered in Israel, announced the successful completion of a large-scale production of exosomes. Innocan's cannabidiol (CBD)-Loaded Exosome (CLX) Therapy project led by Professor Daniel Offen (https://www.danioffenlab.com/prof-dani-offen), PhD, demonstrates the capability of having reliable large-scale production of exosomes and is an important milestone in the CLX Therapy development process. Innocan managed to perform the production of trillions of exosomes in a short period of time in a 3-dimensional bioreactor, and that may lead to economic large-scale exosome production for the CLX. This achievement is expected to pave the way for larger tests and studies. "Innocan is now one of a few public companies in the exosome's science field. Although we are still in the development stage of the CLX platform, large-scale exosome production capabilities are a significant proof of advantage and capability for Innocan, as part of the path to commercialization," said Iris Bincovich, Founder and CEO of Innocan. Innocan Pharma, together with Tel Aviv University and Professor Offen and his team, are developing a new revolutionary cell therapy-based technology, loaded with CBD (cannabidiol), designed to target coronavirus infected lung cells and central nervous system diseases. The CLX Therapy holds the potential to provide a highly synergistic effect of anti-inflammatory properties and help in the recovery of infected lung cells. This product is planned to act as a "guided missile" to the infected lungs, combining the cell-healing properties of exosomes and the anti-inflammatory properties of CBD.
Login Or Register To Read Full Story